A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis.
Aberrant behaviors exhibited by people with developmental disabilities have been well documented. Often, psychotropic medications, especially neuroleptics, have been used to control behaviors such as self-injury, physical aggression, property destruction, and hyperactivity. Serious side effects of these medications have occurred, resulting in litigation and regulation of their use by courts, surveyors, and accrediting bodies. Rules and regulations have been developed requiring that behaviors/symptoms necessitating that medication usage be clearly delineated, that behavior programs be developed and implemented to reduce need, and that the interdisciplinary team approach be used to monitor effectiveness of interventions. Currently, little guidance exists on how behavioral and psychopharmacological interventions should be applied or combined. This paper presents a paradigm for integrating behavior-analytic and psychopharmacological treatment interventions in the treatment of persons with developmental disabilities that meets applicable standards. Our model is consistent with the least restrictive, yet effective treatment philosophy. Implications for research and treatment are presented.
Pyles
D A
DA
W. A. Howe Developmental Center, Tinley Park, IL 60477-3697, USA.
Muniz
K
K
Cade
A
A
Silva
R
R
D001521:Behavior Therapy; D003131:Combined Modality Therapy; D015897:Comorbidity; D017831:Diagnosis, Dual (Psychiatry); D006801:Humans; D008607:Intellectual Disability / Q000175:diagnosis / Q000523:psychology / Q000534:rehabilitation*; D001523:Mental Disorders / Q000175:diagnosis / Q000523:psychology / Q000534:rehabilitation*; D010347:Patient Care Planning; D010348:Patient Care Team; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D012920:Social Behavior Disorders / Q000175:diagnosis / Q000523:psychology / Q000534:rehabilitation*; D012931:Social Environment
D011619:Psychotropic Drugs